Eli Lilly (LLY) Reports Q1 Earnings, Raises 2026 Revenue Outlook by $2B
Published on · Source: cnbc.com
AI Summary
Summarized by AI from the source belowEli Lilly (LLY) reported Q1 earnings of $8.55 per share and revenue of $19.80 billion, surpassing estimates of $6.66 and $17.62 billion, respectively. The company raised its 2026 revenue guidance to $82-$85 billion from $80-$83 billion. Mounjaro's revenue increased 125% to $8.66 billion, while Zepbound generated $4.16 billion in U.S. sales, an 80% year-over-year rise. With a strong 60.1% share of the U.S. obesity market, the robust demand for its products underscores Lilly's market position despite price pressures.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Eli Lilly and Company (LLY)
Eli Lilly is a major pharmaceutical company known for diabetes and obesity treatments and a broad drug pipeline.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier LLY news
- Eli Lilly (LLY) Reports $12.9 Billion in GLP-1 Drug Sales
- Novartis (NVS) drug trials target Lp(a) for heart disease prevention
- Eli Lilly (LLY) Plans $7B Acquisition, P/E at 40 Amid Growth
- Pfizer (PFE) GLP-1 Drug Shows 10%-12% Weight Loss in Trials
- Eli Lilly (LLY) sees GLP-1 windfall, Honeywell (HON) divests unit
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
